News & Views - Page 6 of 54 - Telix Pharmaceuticals Limited

Telix at AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer

We are pleased to announce that Telix is supporting AdMeTech Foundation’s 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer, to be held virtually from September 22-24 2022.

Telix Japan – Telix Luncheon Seminar at WFNMB 2022

We are pleased to announce that Telix will be hosting a Luncheon Seminar at the 13th Congress of the World Federation of Nuclear Medicine and Biology (WFNMB), to be held at the Kyoto International Conference Center from September 7-11 2022.

Take a PSMA journey with Telix at EAU22

As a specialist in urology, Telix is delighted to invite you onboard the PSMA train. Our symposium, taking place during the EAU Congress 2022, will be an opportunity to ensure your PSMA knowledge is right on track. It’s an exciting field, and the train is moving fast, so join our expert travelers as they take you on a journey towards the latest developments in prostate cancer imaging and treatment.

Presentation to Jefferies Global Healthcare Conference

Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies Global Healthcare Conference in New York City on Friday 10 June.

Telix at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

Telix is sponsoring a symposium and presenting the company’s prostate cancer imaging agent and clinical programs at #SNMMI22, being held in Vancouver, Canada from 11-14 June, 2022.

Chief Medical Officer, Dr. Colin Hayward, Discussion with Wilsons Advisory

Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging and therapeutic research pipeline.

Telix at ANZSNM Annual Scientific Meeting 2022

Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15 May.

2nd Joint Telix and Duchembio Symposium – Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists

On World Theranostics Day, with our partner, Duchembio, we are pleased to present the 2nd joint symposium on the clinical utility of PSMA-PET in prostate cancer imaging and key PSMA PET image interpretation for urologists in Korea.

New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts

Telix is pleased to announce the launch of PSMA PET/CT Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in prostate cancer care.

TRALA Study of TLX66 in AL-Amyloidosis Presented at ASH 2021

Telix is pleased to announce the first peer-reviewed results from the Phase I/IIa TRALA (Targeted Radiotherapy for AL Amyloidosis) study of the Company’s bone marrow conditioning investigational candidate TLX66 (90Y-besilesomab) in patients with Systemic Amyloid Light Chain Amyloidosis (AL-Amyloidosis), presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition.